23:25 , Oct 3, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Gram-negative bacterial infection In silico, in vitro and mouse studies identified an oxazolidinone-based LpxC inhibitor that could help treat Gram-negative bacterial infections. In silico screening of analogs of an indazole-based LpxC inhibitor, followed by chemical...
23:17 , Oct 3, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: September 2018

New Therapeutic Targets and Biomarkers: September 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in September. Therapeutic targets are defined as any protein, gene or other molecule that...
15:42 , Sep 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Bacterial infection In silico, cell culture and mouse studies identified a PGA3-derived antimicrobial peptide that could help treat bacterial infection. In silico screening of amino acid sequences of human secreted proteins for structural similarity to...
20:18 , Sep 26, 2018 |  BC Innovations  |  Translation in Brief

Digesting antimicrobial peptides

Synthetic biology researchers at Massachusetts Institute of Technology used a data-mining approach to identify a new antimicrobial peptide derived from a human digestive protein, adding a potential weapon in the battle against antibiotic resistance. As bacteria...
17:35 , Sep 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Pseudomonas Cell culture studies suggest inhibition of P. aeruginosa sodB or combined inhibition of P. aeruginosa relA and spoT could help treat chronic infections by the bacteria and prevent drug resistance. In stationary-phase P. aeruginosa...
15:18 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Gram-negative bacterial infection Mouse studies identified a member of the arylomycin class of bacterial lepB-inhibiting antibiotics that could help treat multidrug resistant (MDR) Gram-negative bacterial infections. Chemical synthesis and in vitro assays of arylomycin...
21:13 , Sep 12, 2018 |  BC Extra  |  Preclinical News

Genentech develops antibiotic against multidrug resistant Gram-negatives

Genentech Inc. researchers have developed arylomycin derivatives with potent activity against Gram-negative bacteria, including multidrug resistant (MDR) strains. The small molecule could represent a notable step forward against Gram-negative bacteria, for which no new class...
03:33 , Aug 17, 2018 |  BC Week In Review  |  Financial News

Infectious company Aridis raises $26M in NASDAQ IPO

Infectious disease mAb company Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) raised $26 million on Aug. 13 through the sale of 2 million shares at $13 in an IPO on NASDAQ. Cantor Fitzgerald, Maxim Group, Laidlaw, Northland Securities...
15:30 , Jul 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Pseudomonas Cell culture and mouse studies suggest miR-138 or its mimetics could help treat Pseudomonas aeruginosa lung infections. In lung samples from a mouse model of P. aeruginosa lung infection, levels of miR-138 were higher...
23:37 , Jul 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Pseudomonas Cell culture and mouse studies suggest inhaled bacteriophage-loaded microparticles could help treat Pseudomonas aeruginosa lung infections. The microparticles consist of porous poly(lactic-co-glycolic acid) (PLGA) polymer shells loaded with a cocktail of three or five...